A distinguished panel of experts in hematologic malignancies builds a lively discussion on recent clinical trials and potential advancements in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
EP. 4: Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
July 22nd 2022Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
EP. 18: Anti-CD20 Regimens and Triplet Therapies in CLL
September 9th 2022Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
EP. 20: Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
September 15th 2022Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.